GlobeNewswire

New Research Reveals Majority of Recruiters Ready for GDPR; Concerns Remain About Sourcing and Hiring Under New Guidelines

Dela

Data from Lever Examines How Organizations are Preparing for GDPR Compliance Specific to Recruiting and Hiring

 

SAN FRANCISCO, March 27, 2018 (GLOBE NEWSWIRE) -- While nearly three quarters of organizations feel confident in their ability to achieve General Data Protection Regulation (GDPR) compliance for their recruiting efforts by the May 25th deadline, most still harbor concerns about how the new regulations will impact their hiring process, according to new research from Lever, the recruiting software for more than 1,500 leading companies around the world. Lever surveyed 500 professionals across the EU and US directly involved in preparing their organizations for GDPR compliance for recruiting.

According to the survey results, 70 percent of respondents believe they will be prepared for GDPR compliant recruiting by May 25th, but preparation doesn't come overnight, or in a silo. Nearly a third of respondents say they are investing significant time and resources into becoming GDPR compliant and 73 percent are working with external or internal legal counsel to prepare.

Despite this high level of preparedness, 61 percent of respondents are concerned about the impact of GDPR on their recruiting and hiring processes, including how they source potential candidates. Respondents were also either 'very concerned' or 'extremely concerned' about adhering to specific requirements included in the regulations, such as:

  • Maintaining full records of recruiting processing activities (52 percent)
  • Determining when to get consent from candidates (50 percent)
  • Determining how long to store a candidate's personal data before deleting it or obtaining consent (47 percent)
  • Selecting software vendors who will enter into GDPR compliant contracts and meet data security requirements (46 percent)

Regardless of these concerns, the overwhelming majority (90 percent) of respondents who are already engaged in sourcing will continue to do so under GDPR.

"The GDPR deadline is quickly approaching, but few are discussing the potential impact these regulations will have on how organizations source, recruit and hire their talent," said Mike Walsh, Director of Product Marketing of Lever. "We hope this research serves as a catalyst within organizations to begin discussing in detail how they will move forward with sourcing candidates under GDPR and the lengths they will go to protect candidate data. At Lever, we have spent significant time working on these issues on behalf of our clients and hope to continue to serve as a resource for recruiters worldwide."

Lever's research also revealed some organizations are unsure how to adhere to regulations related to candidate data. According to the GDPR, organizations must identify their own "lawful basis" for processing personal candidate data. For recruiting, the most common lawful bases are consent and legitimate interest, but it can be a grey area for many recruiters.

For example, respondents are split regarding when to collect consent from candidates. Only 40 percent of respondents will collect consent to contact for jobs they did not apply to, 37 percent will collect consent in order to email candidates they source and 25.5 percent will collect consent when they plan to keep data from candidates who were in their ATS before May 25th, 2018.

Another grey area the survey addressed was determining how long to store candidate data. While GDPR requires companies to only keep personal data for "no longer than is necessary for the purposes for which the personal data are processed," the data showed great variation in how organizations are interpreting this obligation. Some companies will delete candidate data as soon as the job they were tied to closes (23 percent), while others plan to retain candidate data for a year or more (23 percent).

The full research report can be downloaded at this link.

Methodology
From March 2 - 8, 2018, Lever surveyed 500 professionals across the EU and US who are directly involved in preparing their organizations for GDPR compliance for recruiting.

About Lever
Built from the conviction that recruiting is the responsibility of everyone at the company, Lever's applicant tracking and sourcing technology draws the entire team together to source, nurture, interview, and hire top talent through effortless collaboration. Lever has been intentionally designed with integrated ATS and CRM functionality, and features a modern interface that helps employers develop stronger candidate relationships in fewer clicks. 

Lever was founded in 2012 in San Francisco. The company has raised more than $73 million in funding from Adams Street Partners, Scale Venture Partners, Matrix Partners, Y Combinator, Redpoint Ventures, and Correlation Ventures among others. Lever supports the hiring needs of over 1,500 companies around the globe including the teams at Netflix, Hot Topic, KPMG New Zealand, and Cirque du Soleil. With an overall gender ratio of 50:50, Lever is also fiercely committed to building a team culture that celebrates diversity and inclusion. For more information, visit https://www.lever.co.

MEDIA CONTACT:
Ashley Cohen
Traeger Communications
acohen@traegercommunications.com
303-522-0783




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Lever, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum